<DOC>
	<DOCNO>NCT01987804</DOCNO>
	<brief_summary>Up 50 % postmenopausal woman , experience vaginal drynes , i.e . vaginal atrophy consequence due lack estrogen . In addition , vaginal atrophy associate increase pH , create environment susceptible infection . The mucosal epithelium show sign severe senile atrophy cytological examination demonstrate increase number basal parabasal cell reduce number superficial cell . Unlike menopausal symptom ( instance hot flush ) , vaginal symptom generally persist worsen aging.Oxytocin peptide hormone release systemically via posterior pituitary . The well know effect oxytocin role female reproduction facilitation birth breast feeding . Oxytocin also show exert positive effect proliferation human vaginal mucosal cell postmenopausal woman , effect could attribute either direct stimulation new cell formation increase production growth factor . The primary objective investigate dose relationsship topical administrate Vagitocin vaginal mucosal membrane , measure change ( % ) superficial cell 7 week baseline .</brief_summary>
	<brief_title>Dose-relationship Vaginally Administrated Oxytocin Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Naturally postmenopausal ooforectomized woman , completely without menstrual bleeding least four year prior baseline . 2 . &gt; 40 year age . 3 . Moderate severe symptom least one follow criterion vulvar vaginal atrophy associate menopause , accord patient 's selfassessement : vaginal dryness , vaginal and/or vulvar irritation/itching , dysuria , vaginal pain associate sexual activity , presence vaginal bleeding associate sexual activity . 4 . Atrophic mucosa accord investigator 's assessment . 5 . Signed Informed Consent . 1 . Usage sex steroid include phytoestrogens , hormonal intrauterine device herbal medicinal product know estrogenic effect within 3 month prior baseline . 2 . Usage lubricant intravaginal administration baseline . 3 . Vaginal bleed unknown origin . 4 . Vaginal pH â‰¤ 5.0 . 5 . Any ongoing urogenital infection within 7 day prior baseline . 6 . Body Mass Index ( BMI ) &gt; 30 kg/m2 . 7 . Systolic Blood Pressure &gt; 150 mmHg Diastolic Blood Pressure &gt; 90 mmHg baseline . 8 . Any concurrent know suspected tumor disease judge investigator . 9 . Clinically significant medical history ( exclude medically wellcontrolled hypertension hypercholesterolemia ) , abnormal finding physical examination , vital sign , cytology , histology , US examination uterus ovary laboratory analysis may interfere trial objective compromise safety patient judge Investigator . 10 . Concurrent diagnose nephrological hepatic disorder 11 . Diagnosed HIV , Hepatitis B C 12 . Known suspected drug alcohol abuse , within 12 month prior baseline . 13 . Known suspected allergy ingredient trial product . 14 . Incapacity perform trial procedure , judge investigator . 15 . Participation interventional clinical trial within 3 month prior baseline .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>